Antibodies is an international, peer-reviewed, open access journal on immunoglobulins, published quarterly online by MDPI.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
  • Journal Rank: CiteScore - Q1 (Drug Discovery)
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 4.9 days (median values for papers published in this journal in the second half of 2023).
  • Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Impact Factor: 4.7 (2022); 5-Year Impact Factor: 4.9 (2022)
Add your e-mail address to receive forthcoming issues of this journal:
Topic in Antibodies, Cancers, Immuno, IJMS, Vaccines
Anti-Tumor Immune Responses 2.0 Topic Editors: Massimo Zollo, Renata Grifantini
Deadline: 31 August 2024
Special Issue in Antibodies
Novel Strategies and Technologies for the Development of Tumor-Specific Antibodies Guest Editor: Alexander J. Bankovich
Deadline: 29 March 2024
Special Issue in Antibodies
Autoimmune and Inflammatory Rheumatic Diseases: Potential Biomarkers, Antibodies Response and New Therapies Guest Editor: Marino Paroli
Deadline: 30 April 2024
Special Issue in Antibodies
Unravelling Effector Functions of B cells in Infectious Diseases and Cancer Guest Editor: Farhat Afrin
Deadline: 20 May 2024
Special Issue in Antibodies
Antiphospholipid Antibodies Guest Editors: Md Asiful Islam, Przemysław Kotyla
Deadline: 30 June 2024
Topical Collection in Antibodies
Computational Antibody and Antigen Design Collection Editor: Buyong Ma
Back to TopTop